IceCure Medical Ltd. (NASDAQ:ICCM) Given Average Rating of “Hold” by Analysts

Shares of IceCure Medical Ltd. (NASDAQ:ICCM) have been assigned a consensus recommendation of “Hold” from the five brokerages that are presently covering the stock, MarketBeat reports. Two research analysts have rated the stock with a sell rating and three have issued a buy rating on the company. The average 1 year target price among brokers that have covered the stock in the last year is $52.50.

Several analysts have recently issued reports on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of IceCure Medical in a research note on Friday, July 17th. Zacks Research lowered shares of IceCure Medical from a “hold” rating to a “strong sell” rating in a research report on Friday, August 14th. Wall Street Zen upgraded shares of IceCure Medical from a “sell” rating to a “hold” rating in a report on Saturday. Finally, Maxim Group reduced their price objective on shares of IceCure Medical from $90.00 to $30.00 and set a “buy” rating for the company in a research report on Thursday, May 14th.

IceCure Medical Stock Up 1.4%

Shares of NASDAQ:ICCM opened at $2.23 on Friday. The business’s 50 day moving average is $3.24 and its 200 day moving average is $8.14. IceCure Medical has a 12-month low of $2.12 and a 12-month high of $42.00. The stock has a market cap of $7.64 million, a price-to-earnings ratio of -0.26 and a beta of 0.45.

IceCure Medical (NASDAQ:ICCM) last released its quarterly earnings results on Tuesday, June 30th. The company reported ($1.60) EPS for the quarter. IceCure Medical had a negative net margin of 427.67% and a negative return on equity of 174.26%. The company had revenue of $0.91 million during the quarter. As a group, equities research analysts expect that IceCure Medical will post -4.61 earnings per share for the current year.

Hedge Funds Weigh In On IceCure Medical

An institutional investor recently bought a new stake in IceCure Medical stock. Jane Street Group LLC purchased a new stake in shares of IceCure Medical Ltd. (NASDAQ:ICCM) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 109,638 shares of the company’s stock, valued at approximately $67,000. Jane Street Group LLC owned about 0.16% of IceCure Medical at the end of the most recent quarter. 0.62% of the stock is currently owned by institutional investors.

IceCure Medical Company Profile

IceCure Medical Ltd. (NASDAQ: ICCM) is a clinical-stage medical device company specializing in the development and commercialization of proprietary cryoablation systems for the treatment of tumors and other pathological tissues. The company’s core technology employs a unique liquid-nitrogen-based platform to deliver rapid cooling through fine-gauge cryoprobes, enabling precise and minimally invasive tissue ablation under imaging guidance. IceCure’s lead product, ProSense, is designed to offer a single-probe approach that can be deployed in an outpatient setting, reducing procedure time and patient recovery periods.

Originally founded in Israel, IceCure Medical obtained its first CE mark for the treatment of benign breast tumors and fibroadenomas in 2017.